Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evorpacept - ALX Oncology

Next Previous
Drug Profile

Evorpacept - ALX Oncology

Alternative Names: ALX-148; CD47/SIRPa-blocking Agent ALX 148; SIRPa Variant ALX 148

Latest Information Update: 13 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexo Therapeutics
  • Developer ALX Oncology; Eli Lilly and Company; Merck & Co; Merck Sharp & Dohme; Quantum Leap Healthcare Collaborative; University of California; Zymeworks
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
  • Mechanism of Action CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Adenocarcinoma
  • Phase II Colorectal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Phase I/II Acute myeloid leukaemia; HER2 positive breast cancer; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Breast cancer; Urogenital cancer

Most Recent Events

  • 28 Apr 2025 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT07007559)
  • 28 Apr 2025 ALX Oncology initiates enrolment in the ASPEN-09 phase I/II trials inHER2-positive breast cancer(Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT07007559)
  • 25 Apr 2025 Pooled adverse events data from phase II ASPEN-03 and ASPEN-04 trials in Squamous cell cancer released by ALX oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top